Special Issue

Applications and Perspectives of Metal Chelators and Metal Complexes in Drug Development

Message from the Guest Editor

The aim of this Special Issue is to comprehensively explore the applications and future perspectives of metal chelators and metal complexes in drug development. It will cover a wide scope, from their fundamental chemical properties to their clinical applications across various disease areas. Cutting-edge research focusing on the development of novel metalbased drugs with enhanced selectivity and efficacy is welcomed. For example, research investigating the use of metal complexes in targeted cancer therapy and the application of metal chelators in treating neurodegenerative diseases by modulating metal ion homeostasis, as well as applications in metabolomic and inflammatory diseases, is of particular interest. We welcome original research articles, reviews, and perspectives that either experimentally validate new metal-based drug candidates or provide in-depth theoretical analyses of their potential applications in drug development.

Guest Editor

Dr. Joanna Izabela Lachowicz

Department of Population Health, Division of Environmental Health, Occupational Medicine and Epidemiology, Wroclaw Medical University, Mikulicza-Radeckiego 7, PL 50-368 Wroclaw, Poland

Deadline for manuscript submissions

25 October 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/233187

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceutica

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

